Investment Thesis
Tenaya Therapeutics is a pre-revenue biotech company with strong balance sheet fundamentals (5.75x liquidity, minimal debt, $80.9M cash) but burning $19.2M annually with only $225K in revenue. While net losses are improving 55% YoY, the company remains entirely dependent on successful drug development and lacks commercial traction or visible profitability path.
Strengths
- Excellent liquidity position with 5.75x current ratio and $80.9M cash reserves
- Conservative balance sheet with zero long-term debt and strong stockholders equity of $106.2M
- Significant operational improvement with 55% YoY net loss reduction showing positive momentum
Risks
- Severe cash burn rate of $19.2M annually depletes $80.9M cash position in ~4 years without revenue generation or capital raise
- Pre-revenue company with only $225K revenue indicating no commercial traction or market validation
- Biotech execution risk: pipeline success is entirely dependent on clinical trial outcomes and regulatory approval with no revenue visibility
Key Metrics to Watch
- Cash runway and burn rate trend relative to clinical development milestones
- Clinical trial progression and any partnership or licensing agreements
- Revenue ramp and path to positive operating cash flow
Financial Metrics
Revenue
225.0K
Net Income
-19.3M
EPS (Diluted)
$-0.09
Free Cash Flow
-19.2M
Total Assets
135.1M
Cash
80.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-8,917.8%
Net Margin
-8,565.3%
ROE
-18.1%
ROA
-14.3%
FCF Margin
-8,553.3%
Balance Sheet & Liquidity
Current Ratio
5.75x
Quick Ratio
5.75x
Debt/Equity
0.00x
Debt/Assets
21.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T12:43:24.347054 |
Data as of: 2026-03-31 |
Powered by Claude AI